Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis.

IF 8.5 1区 医学 Q1 ONCOLOGY
Sagar R Patel, Mikael Rauf, Yimin Geng, David Hinojosa-Gonzalez, Joseph B Black, Taeweon Lee, Amanda A Myers, Charles Guo, Roger Li, Joshua J Meeks, Piyush Agarwal, Stephen Williams, Omar Alhalabi, Andrea Necchi, Laura S Mertens, Paolo Gontero, Neema Navai, Ashish M Kamat
{"title":"Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis.","authors":"Sagar R Patel, Mikael Rauf, Yimin Geng, David Hinojosa-Gonzalez, Joseph B Black, Taeweon Lee, Amanda A Myers, Charles Guo, Roger Li, Joshua J Meeks, Piyush Agarwal, Stephen Williams, Omar Alhalabi, Andrea Necchi, Laura S Mertens, Paolo Gontero, Neema Navai, Ashish M Kamat","doi":"10.1016/j.euo.2026.10.001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clinical T1 micropapillary urothelial carcinoma of the bladder is an aggressive variant histology for which early radical cystectomy (RC) is commonly recommended. However, there remain conflicting data on whether conditions in carefully selected patients may be managed with initial bladder-sparing approaches without compromising oncologic outcomes.</p><p><strong>Objective: </strong>The objective is to systematically review and synthesize the available literature comparing bladder-sparing approaches, such as Bacillus Calmette-Guerin (BCG) therapy, and early RC outcomes in clinical stage 1 primary tumor (cT1) micropapillary carcinoma of the bladder.</p><p><strong>Design, setting, and participants: </strong>A systematic search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and Cochrane Handbook for Systematic Reviews of Interventions.</p><p><strong>Outcome measurement and statistical analysis: </strong>The primary end points were overall survival (OS) and cancer-specific survival (CSS). The included articles were descriptively assessed and time-to-event analysis was performed for select endpoints.</p><p><strong>Results and limitations: </strong>Among 461 identified reports, nine retrospective studies met the criteria for quantitative analysis, encompassing 9402 patients of whom 9287 (99%) had non-muscle-invasive bladder cancer (NMIBC) and 1033 (11%) had a micropapillary subtype. A total of 625 patients (62%) underwent bladder-sparing approaches, whereas 392 (39%) underwent early RC. Of the bladder-sparing approaches, 88% of patients received intravesical BCG therapy. For a bladder-sparing approach for cT1 disease with a micropapillary component, pooled unadjusted hazard ratios were not statistically significant for CSS (hazard ratio [HR] 1.32, 95% confidence interval [CI] 0.60-2.88, p = 0.5) and OS (HR 0.85, 95% CI 0.68-1.07, p = 0.16) compared with early RC. Data evaluating bladder-sparing strategies beyond BCG were limited.</p><p><strong>Conclusions: </strong>NMIBC with micropapillary features is an aggressive disease conventionally managed with early RC. In retrospective cohorts of selected patients with micropapillary cT1, available unadjusted data did not provide clear evidence of statistically significant differences in CSS or OS between initial bladder-sparing approaches and early RC.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.5000,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2026.10.001","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Clinical T1 micropapillary urothelial carcinoma of the bladder is an aggressive variant histology for which early radical cystectomy (RC) is commonly recommended. However, there remain conflicting data on whether conditions in carefully selected patients may be managed with initial bladder-sparing approaches without compromising oncologic outcomes.

Objective: The objective is to systematically review and synthesize the available literature comparing bladder-sparing approaches, such as Bacillus Calmette-Guerin (BCG) therapy, and early RC outcomes in clinical stage 1 primary tumor (cT1) micropapillary carcinoma of the bladder.

Design, setting, and participants: A systematic search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and Cochrane Handbook for Systematic Reviews of Interventions.

Outcome measurement and statistical analysis: The primary end points were overall survival (OS) and cancer-specific survival (CSS). The included articles were descriptively assessed and time-to-event analysis was performed for select endpoints.

Results and limitations: Among 461 identified reports, nine retrospective studies met the criteria for quantitative analysis, encompassing 9402 patients of whom 9287 (99%) had non-muscle-invasive bladder cancer (NMIBC) and 1033 (11%) had a micropapillary subtype. A total of 625 patients (62%) underwent bladder-sparing approaches, whereas 392 (39%) underwent early RC. Of the bladder-sparing approaches, 88% of patients received intravesical BCG therapy. For a bladder-sparing approach for cT1 disease with a micropapillary component, pooled unadjusted hazard ratios were not statistically significant for CSS (hazard ratio [HR] 1.32, 95% confidence interval [CI] 0.60-2.88, p = 0.5) and OS (HR 0.85, 95% CI 0.68-1.07, p = 0.16) compared with early RC. Data evaluating bladder-sparing strategies beyond BCG were limited.

Conclusions: NMIBC with micropapillary features is an aggressive disease conventionally managed with early RC. In retrospective cohorts of selected patients with micropapillary cT1, available unadjusted data did not provide clear evidence of statistically significant differences in CSS or OS between initial bladder-sparing approaches and early RC.

保留膀胱治疗与早期根治性膀胱切除术治疗cT1微乳头状膀胱癌的临床结果:系统回顾和荟萃分析。
背景:临床T1型膀胱微乳头状尿路上皮癌是一种侵袭性的组织学变异型,通常推荐早期根治性膀胱切除术(RC)。然而,对于精心挑选的患者是否可以在不影响肿瘤预后的情况下采用初始膀胱保留入路进行治疗,仍然存在相互矛盾的数据。目的:系统回顾和综合现有文献,比较保膀胱入路,如卡介苗(Bacillus Calmette-Guerin, BCG)治疗与临床1期原发性肿瘤(cT1)膀胱微乳头状癌的早期RC预后。设计、设置和参与者:根据系统评价和荟萃分析声明的首选报告项目和Cochrane干预措施系统评价手册进行系统搜索。结果测量和统计分析:主要终点为总生存期(OS)和癌症特异性生存期(CSS)。对纳入的文章进行描述性评估,并对选定的终点进行时间到事件的分析。结果和局限性:在461份确定的报告中,9项回顾性研究符合定量分析的标准,包括9402例患者,其中9287例(99%)为非肌肉浸润性膀胱癌(NMIBC), 1033例(11%)为微乳头状亚型。共有625例(62%)患者接受了膀胱保留入路,而392例(39%)患者接受了早期RC。在保膀胱入路中,88%的患者接受膀胱内BCG治疗。对于有微乳头状成分的cT1疾病的保膀胱入路,与早期RC相比,CSS(风险比[HR] 1.32, 95%可信区间[CI] 0.60-2.88, p = 0.5)和OS(风险比[HR] 0.85, 95% CI 0.68-1.07, p = 0.16)的合并未调整风险比无统计学意义。评估BCG以外的膀胱保留策略的数据有限。结论:具有微乳头状特征的NMIBC是一种侵袭性疾病,通常采用早期RC治疗。在选定的微乳头状cT1患者的回顾性队列中,现有的未经调整的数据没有提供明确的证据,证明初始膀胱保留入路和早期RC在CSS或OS方面存在统计学上的显著差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.50
自引率
2.40%
发文量
128
审稿时长
20 days
期刊介绍: Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书